MannKind (MNKD) to Release Earnings on Thursday

MannKind (NASDAQ:MNKD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $75.86 million for the quarter.

MannKind (NASDAQ:MNKD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, meeting analysts' consensus estimates of $0.03. The firm had revenue of $76.78 million for the quarter, compared to analysts' expectations of $74.99 million. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 1.0 %

MannKind stock opened at $5.00 on Friday. MannKind has a 12-month low of $4.17 and a 12-month high of $7.63. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of 71.43 and a beta of 1.22. The firm has a 50 day moving average of $4.94 and a 200 day moving average of $5.89.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MNKD. StockNews.com raised shares of MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Mizuho initiated coverage on MannKind in a research note on Thursday, April 10th. They issued an "outperform" rating and a $12.00 price objective for the company. Finally, Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of MannKind in a research note on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $9.56.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.